A study of the drug RYZ101 for meningioma that grows or comes back
Official title: RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether a radioactive drug called RYZ101 can help with meningioma.
Read our full plain-language summary
What the trial team says
This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.
Key facts
- Registry number
- NCT07150806
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Recurrent Meningioma
Where it is running
This trial lists 1 site.
-
Ohio
- Ohio State University Comprehensive Cancer Center (Columbus)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.